Several analysts have recently updated their ratings and price targets for Kalaris Therapeutics (NASDAQ: KLRS):
- 6/23/2026 – Kalaris Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 6/15/2026 – Kalaris Therapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.
- 6/14/2026 – Kalaris Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
- 6/9/2026 – Kalaris Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 6/6/2026 – Kalaris Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
- 5/23/2026 – Kalaris Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
- 5/14/2026 – Kalaris Therapeutics is now covered by Wedbush. They set an “outperform” rating and a $17.00 price target on the stock.
- 5/14/2026 – Kalaris Therapeutics is now covered by Wedbush. They set an “outperform” rating and a $17.00 price target on the stock.
- 5/13/2026 – Kalaris Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
- 5/13/2026 – Kalaris Therapeutics had its price target lowered by Citizens Jmp from $26.00 to $25.00. They now have a “market outperform” rating on the stock.
Insider Activity at Kalaris Therapeutics
In other news, Director Srinivas Akkaraju bought 244,300 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $4.83 per share, with a total value of $1,179,969.00. Following the transaction, the director directly owned 2,224,147 shares in the company, valued at $10,742,630.01. This represents a 12.34% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 68.10% of the stock is currently owned by corporate insiders.
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
Featured Stories
- Five stocks we like better than Kalaris Therapeutics
- Manchester United’s Stock Rally Faces a Test Beyond Old Trafford
- Overclocking Qualcomm: Rewiring the AI Compute Market
- 3 Top Financial Institutions Announce Over $70 Billion in Share Repurchases
- Rezolve AI Stock Has a Short-Squeeze Setup, But Execution Comes First
Receive News & Ratings for Kalaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
